6 Aptamers for Targeted Therapy
175
198. Fan X, Sun L, Wu Y, Zhang L, Yang Z (2016) Bioactivity of 2’-deoxyinosine-incorporated
aptamer AS1411. Sci Rep 6 (2045–2322 Electronic):25799
199. Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon
JH (2016) Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating
galectin-14. PLoS ONE 11(8):e0160822
200. Rajabnejad SH, Mokhtarzadeh A, Abnous K, Taghdisi SM, Ramezani M, Razavi BM (2018)
Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer. Drug Dev Ind
Pharm 44(6):982–987
201. Tekie FSM, Soleimani M, Zakerian A, Dinarvand M, Amini M, Dinarvand R, Arefian
E, Atyabi F (2018) Glutathione responsive chitosan-thiolated dextran conjugated miR-145
nanoparticles targeted with AS1411 aptamer for cancer treatment. Carbohydr Polym 201
(1879–1344 Electronic):131–140
202. Yang SD, Ren ZX, Chen MT, Wang Y, You BG, Chen WL, Qu CX, Liu Y, Zhang XN (2018)
Nucleolin-targeting AS1411-aptamer-modified graft polymeric micelle with dual pH/redox
sensitivity designed to enhance tumor therapy through the codelivery of doxorubicin/TLR4
siRNA and suppression of invasion. Mol Pharmaceut 15(1):314–325
203. Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, Maekawa T,
Kumar DS (2012) AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell
targeting and drug delivery. Biotechnol Bioeng 109(11):2920–2931
204. Saravanakumar K, Hu X, Shanmugam S, Chelliah R, Sekar P, Oh DH, Vijayakumar
S, Kathiresan K, Wang MH (2019) Enhanced cancer therapy with pH-dependent and
aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid)
nanoparticles. Arch Biochem Biophys 671 (1096–0384 Electronic):143–151
205. Alibolandi M, Ramezani M, Abnous K, Hadizadeh F (2016) AS1411 Aptamer-Decorated
biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the
targeted delivery of gemcitabine to non-small cell lung cancer in vitro. J Pharm Sci
105(5):1741–1750
206. Chen HC, Tian JW, Liu DY, He WJ, Guo ZJ (2017) Dual aptamer modified dendrigraft polyL-lysine nanoparticles for overcoming multi-drug resistance through mitochondrial targeting.
J Mater Chem B 5(5):972–979
207. Barzegar Behrooz A, Nabavizadeh F, Adiban J, Shafiee Ardestani M, Vahabpour R,
Aghasadeghi MR, Sohanaki H (2017) Smart bomb AS1411 aptamer-functionalized/PAMAM
dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer. Clin Exp
Pharmacol Physiol 44(1):41–51
208. Ayatollahi S, Salmasi Z, Hashemi M, Askarian S, Oskuee RK, Abnous K, Ramezani M (2017)
Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into
lung cancer cells. Int J Biochem Cell B 92 (1878–5875 Electronic):210–217
209. Luo Z, Yan Z, Jin K, Pang Q, Jiang T, Lu H, Liu X, Pang Z, Yu L, Jiang X
(2017) Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-gammaglutamylglutamine)-paclitaxel nanoconjugates. J Colloid Interface Sci 490:783–796
210. Yazdian-Robati R, Ramezani M, Jalalian SH, Abnous K, Taghdisi SM (2016) Targeted
delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo.
Pharm Res 33(9):2289–2297
211. Taghdisi SM, Danesh NM, Ramezani M, Lavaee P, Jalalian SH, Robati RY, Abnous K (2016)
Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells
by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm 102 (1873–3441
Electronic):152–158
212. Taghdisi SM, Danesh NM, Ramezani M, Yazdian-Robati R, Abnous K (2018) A novel AS1411
aptamer-based three-way junction pocket DNA nanostructure loaded with doxorubicin for
targeting cancer cells in vitro and in vivo. Mol Pharm 15(5):1972–1978
213. Abnous K, Danesh NM, Ramezani M, Charbgoo F, Bahreyni A, Taghdisi SM (2018) Targeted
delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of
AS1411 and FOXM1 aptamers. Expert Opin Drug Deliv 15(11):1045–1052
175
198. Fan X, Sun L, Wu Y, Zhang L, Yang Z (2016) Bioactivity of 2’-deoxyinosine-incorporated
aptamer AS1411. Sci Rep 6 (2045–2322 Electronic):25799
199. Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon
JH (2016) Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating
galectin-14. PLoS ONE 11(8):e0160822
200. Rajabnejad SH, Mokhtarzadeh A, Abnous K, Taghdisi SM, Ramezani M, Razavi BM (2018)
Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer. Drug Dev Ind
Pharm 44(6):982–987
201. Tekie FSM, Soleimani M, Zakerian A, Dinarvand M, Amini M, Dinarvand R, Arefian
E, Atyabi F (2018) Glutathione responsive chitosan-thiolated dextran conjugated miR-145
nanoparticles targeted with AS1411 aptamer for cancer treatment. Carbohydr Polym 201
(1879–1344 Electronic):131–140
202. Yang SD, Ren ZX, Chen MT, Wang Y, You BG, Chen WL, Qu CX, Liu Y, Zhang XN (2018)
Nucleolin-targeting AS1411-aptamer-modified graft polymeric micelle with dual pH/redox
sensitivity designed to enhance tumor therapy through the codelivery of doxorubicin/TLR4
siRNA and suppression of invasion. Mol Pharmaceut 15(1):314–325
203. Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, Maekawa T,
Kumar DS (2012) AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell
targeting and drug delivery. Biotechnol Bioeng 109(11):2920–2931
204. Saravanakumar K, Hu X, Shanmugam S, Chelliah R, Sekar P, Oh DH, Vijayakumar
S, Kathiresan K, Wang MH (2019) Enhanced cancer therapy with pH-dependent and
aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid)
nanoparticles. Arch Biochem Biophys 671 (1096–0384 Electronic):143–151
205. Alibolandi M, Ramezani M, Abnous K, Hadizadeh F (2016) AS1411 Aptamer-Decorated
biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the
targeted delivery of gemcitabine to non-small cell lung cancer in vitro. J Pharm Sci
105(5):1741–1750
206. Chen HC, Tian JW, Liu DY, He WJ, Guo ZJ (2017) Dual aptamer modified dendrigraft polyL-lysine nanoparticles for overcoming multi-drug resistance through mitochondrial targeting.
J Mater Chem B 5(5):972–979
207. Barzegar Behrooz A, Nabavizadeh F, Adiban J, Shafiee Ardestani M, Vahabpour R,
Aghasadeghi MR, Sohanaki H (2017) Smart bomb AS1411 aptamer-functionalized/PAMAM
dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer. Clin Exp
Pharmacol Physiol 44(1):41–51
208. Ayatollahi S, Salmasi Z, Hashemi M, Askarian S, Oskuee RK, Abnous K, Ramezani M (2017)
Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into
lung cancer cells. Int J Biochem Cell B 92 (1878–5875 Electronic):210–217
209. Luo Z, Yan Z, Jin K, Pang Q, Jiang T, Lu H, Liu X, Pang Z, Yu L, Jiang X
(2017) Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-gammaglutamylglutamine)-paclitaxel nanoconjugates. J Colloid Interface Sci 490:783–796
210. Yazdian-Robati R, Ramezani M, Jalalian SH, Abnous K, Taghdisi SM (2016) Targeted
delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo.
Pharm Res 33(9):2289–2297
211. Taghdisi SM, Danesh NM, Ramezani M, Lavaee P, Jalalian SH, Robati RY, Abnous K (2016)
Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells
by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm 102 (1873–3441
Electronic):152–158
212. Taghdisi SM, Danesh NM, Ramezani M, Yazdian-Robati R, Abnous K (2018) A novel AS1411
aptamer-based three-way junction pocket DNA nanostructure loaded with doxorubicin for
targeting cancer cells in vitro and in vivo. Mol Pharm 15(5):1972–1978
213. Abnous K, Danesh NM, Ramezani M, Charbgoo F, Bahreyni A, Taghdisi SM (2018) Targeted
delivery of doxorubicin to cancer cells by a cruciform DNA nanostructure composed of
AS1411 and FOXM1 aptamers. Expert Opin Drug Deliv 15(11):1045–1052